Arvinas (ARVN) Financials: History & Chart

Arvinas, Inc.(ARVN)

Biotechnology · New Haven, CT

$7.42-0.04 (-0.54%)

Delayed quote: Oct 6, 2026, 9:34 AM EDT

About Arvinas, Inc.

Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.

New Haven, CT

246 employees

www.arvinas.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Randy Teel

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	316.70M	249.70M	15.60M	9.50M	41.90M	22.40M	188.80M	59.20M	102.40M
Cost of Goods Sold	11.30M	9.00M	1.10M	1.20M	0.00	0.00	0.00	0.00	0.00
Gross Profit	305.40M	240.70M	14.50M	8.30M	41.90M	22.40M	188.80M	59.20M	102.40M
Gross Profit Margin	96.4%	96.4%	92.9%	87.4%	100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	319.50M	76.60M	77.20M	80.00M	85.70M	93.90M	117.40M	117.40M	162.70M
Research & Development	238.40M	52.60M	60.00M	61.10M	64.70M	68.60M	90.80M	83.30M	86.90M
Selling, General & Administrative	85.20M	24.00M	17.20M	22.40M	21.60M	25.30M	26.60M	34.10M	75.80M
Operating Income (EBIT)	-14.10M	164.10M	-62.70M	-71.70M	-43.80M	-71.50M	71.40M	-58.20M	-60.30M
Operating Margin	-4.5%	65.7%	-401.9%	-754.7%	-104.5%	-319.2%	37.8%	-98.3%	-58.9%
Income Before Tax (EBT)	10.10M	169.60M	-57.50M	-67.20M	-34.80M	-61.50M	83.10M	-45.50M	-48.60M
Interest Income	29.90M	5.50M	6.40M	9.00M	9.00M	10.30M	11.70M	12.90M	14.30M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	24.20M	5.50M	5.20M	4.50M	9.00M	10.00M	11.70M	12.70M	11.70M
Net Income	9.30M	169.40M	-57.60M	-67.40M	-35.10M	-61.20M	82.90M	-45.10M	-49.20M
Income Tax Expense	800K	200K	100K	200K	300K	-300K	200K	-400K	600K
Net Profit Margin	2.9%	67.8%	-369.2%	-709.5%	-83.8%	-273.2%	43.9%	-76.2%	-48.0%
EBITDA	-10.30M	164.80M	-61.60M	-70.50M	-43.00M	-70.10M	72.70M	-56.60M	-59.20M
EBITDA Margin	-3.3%	66.0%	-394.9%	-742.1%	-102.6%	-312.9%	38.5%	-95.6%	-57.8%
Depreciation & Amortization	3.80M	700K	1.10M	1.20M	800K	1.40M	1.30M	1.60M	1.10M
EPS Basic	0.19	2.61	-0.90	-1.04	-0.48	-0.84	1.14	-0.63	-0.68
EPS Diluted	0.16	2.58	-0.90	-1.04	-0.48	-0.84	1.14	-0.63	-0.68
Weighted Average Basic Shares	64.80M	64.80M	64.00M	64.90M	72.90M	72.80M	72.50M	72.10M	72.10M
Weighted Average Diluted Shares	65.70M	65.70M	64.00M	64.90M	72.90M	73.00M	72.70M	72.10M	72.10M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	262.60M	263.40M	78.50M	131.40M	53.60M	25.90M	42.98M	14.32M
Cost of Goods Sold	5.20M	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	257.40M	263.40M	78.50M	131.40M	53.60M	25.90M	42.98M	14.32M
Gross Profit Margin	98.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	372.30M	513.60M	480.00M	394.60M	242.00M	146.70M	94.50M	58.13M
Research & Development	282.90M	348.20M	379.70M	315.00M	180.40M	108.40M	67.19M	45.19M
Selling, General & Administrative	89.40M	165.40M	100.30M	79.60M	61.60M	38.30M	27.31M	12.93M
Operating Income (EBIT)	-114.90M	-250.20M	-401.50M	-263.20M	-188.40M	-120.80M	-51.52M	-43.80M
Operating Margin	-43.8%	-95.0%	-511.5%	-200.3%	-351.5%	-466.4%	-119.9%	-305.8%
Income Before Tax (EBT)	-80.50M	-198.30M	-366.40M	-261.60M	-191.00M	-119.30M	-70.30M	-41.48M
Interest Income	22.00M	54.80M	38.80M	12.00M	1.80M	3.59M	4.60M	2.47M
Interest Expense	N/A	N/A	N/A	N/A	100K	65K	100K	57K
Other Income/Expense	34.40M	51.90M	35.10M	1.60M	-2.60M	1.50M	-18.79M	2.32M
Net Income	-80.80M	-198.90M	-367.30M	-282.50M	-191.00M	-119.30M	-70.29M	-41.48M
Income Tax Expense	300K	600K	900K	20.90M	0.00	0.00	0.00	0.00
Net Profit Margin	-30.8%	-75.5%	-467.9%	-215.0%	-356.3%	-460.6%	-163.6%	-289.6%
EBITDA	-109.70M	-243.60M	-394.80M	-255.00M	-182.40M	-117.60M	-49.27M	-43.10M
EBITDA Margin	-41.8%	-92.5%	-502.9%	-194.1%	-340.3%	-454.1%	-114.6%	-300.9%
Depreciation & Amortization	5.20M	6.60M	6.70M	8.20M	6.00M	3.20M	2.25M	706K
EPS Basic	-1.28	-2.77	-6.62	-5.31	-3.82	-3.02	-1.89	-1.31
EPS Diluted	-1.28	-2.77	-6.62	-5.31	-3.82	-3.02	-1.89	-1.31
Weighted Average Basic Shares	64.90M	71.90M	55.50M	53.20M	50.00M	39.53M	32.93M	31.63M
Weighted Average Diluted Shares	64.90M	71.90M	55.50M	53.20M	50.00M	39.53M	32.93M	31.63M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.